Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLCMarket Beat·Aug 9 at 03:56 AMBEAM-4.81%JHG0.00%
Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street ZenMarket Beat·Aug 8 at 12:18 AMBEAM-4.81%
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest ResultsSimplywall·Aug 7 at 10:56 AMBEAM-4.81%
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q SummaryTradingView·Aug 4 at 06:21 AMBEAM-4.81%
Beam Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 490 KEarnings Watch·Aug 4 at 06:11 AMBEAM-4.81%
Beam Therapeutics Q2 FY26 net loss widens to $122.7 million; revenue drops to $490,000PUBT·Aug 4 at 06:06 AMBEAM-4.81%
Cathie Wood is buying this up-and-coming biotech stock. Should you follow her lead?MSN·Jul 20 at 01:43 PMBEAM-4.81%
ARK Invest snaps up $16.7M in SPCX shares, trims Deere exposureMSN·Jul 16 at 03:57 AMTWST-3.29%TXG-2.03%
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal BattleUnusual Whales·Jul 8 at 01:27 PMBEAM-4.81%PRME-4.13%
Prime Medicine wins arbitration with Beam over AATD therapy PM647PUBT·Jul 8 at 07:04 AMPRME-4.13%BEAM-4.81%
Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM)Simplywall·Jul 7 at 03:01 AMBEAM-4.81%
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $49.87, Implies 43% UpsideTradingView·Jul 3 at 11:20 PMBEAM-4.81%
Beam Therapeutics CEO John M. Evans disposes of 49,000 common shares worth $1.72 millionPUBT·Jul 1 at 03:05 PMBEAM-4.81%
Beam Therapeutics (NASDAQ:BEAM) Insider Sells $1,172,024.64 in StockMarket Beat·Jun 29 at 02:07 PMBEAM-4.81%
